← Back to Nuqta Atlas
Editorially curated · sa-sfda-pgx-pharmacovigilance
SFDA Pharmacogenomics-Pharmacovigilance Project
Links pharmacogenomic biomarkers to pharmacovigilance through biomarker-associated medicine lists, label assessment and safety-signal review.
01 / Project overview
What the record establishes.
- Geographic scope
- National medicines regulation and adverse-event reporting
- Project type
- Regulatory pharmacogenomics initiative
- Research domain
- Drug safety and pharmacogenomics
- Years
- 2023–
- Lifecycle status
- active
- Status basis
- The SFDA lists the project as a drug-safety initiative initiated in 2023; public scale or output metrics are not provided.
- Status evidence date
- 2026-08-15
- Scale
- No public patient, medicine or signal count located.
02 / Organizations and population
Who and what the project connects.
- Lead organizations
- Saudi Food and Drug Authority
- Partner organizations
- Not stated
- Organism / population
- Medicines and adverse-event reports in Saudi Arabia
03 / Data and access
What exists and how it can be reached.
Data types
- pharmacogenomic biomarkers
- adverse-event reports
- medicine labels
- safety signals
Data access
Regulatory data; public initiative description only
Identifiers
No public accession or identifier is listed for this record.
04 / Evidence and provenance
Why the record is included.
Inclusion basis
Named national regulatory program explicitly integrating pharmacogenomics and pharmacovigilance.
Editorial note
National regulatory initiative, not a recruited patient cohort; current outputs are not public.
Sources
- primary record source Verified 2026-08-15
Release v0.2.0